Nuvation Bio outlines potential Europe approval in first half of next year with ~$30M milestone, as IBTROZI posts 18% se

Nuvation Bio Q3 2026 earnings: IBTROZI growth, ROS1 market softness, safusidenib progress, and cash runway.

CryptoAlerta — análise de criptomoedas e mercado em tempo real